Lymphoma: all 5,623 studies

Page 5 of 57. Open to participants first (823), then studies with results posted, then the rest; newest registration first within each.

• AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.RecruitingNCT06137144Phase 1/2
• A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell LymphomaRecruitingNCT06136351Phase 2
• Clinical Study of OR for Second-line Treatment of Refractory MZLRecruitingNCT06134284Phase 4
• Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid TumorsRecruitingNCT06132503Phase 1
• Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a SolutionRecruitingNCT06131801
• IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic CancersRecruitingNCT06119685Phase 1/2
• Lapelga vs GastrofilNot yet recruitingNCT06116734Phase 3
• A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's LymphomaRecruitingNCT06104553Phase 1/2
• CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and LymphomaRecruitingNCT06101381Phase 1/2
• First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive LymphomaNot yet recruitingNCT06097455Early Phase 1
• A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCLRecruitingNCT06086197Phase 2
• A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell LymphomaRecruitingNCT06084936Phase 3
• Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center StudyRecruitingNCT06083701Phase 1/2
• CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic LeukemiaRecruitingNCT06081478Phase 2
• Compassionate Use Study of NHWD-870 in Patients With Advanced Solid Tumors or Lymphomas Carrying NUT RearrangementRecruitingNCT06073938
• A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell LymphomaRecruitingNCT06071871Phase 2
• Navigating the Clinical Research Process for LymphomaNot yet recruitingNCT06070246
• RCT of Intralesional Rituximab Injection Versus Involved Site Radiation Therapy in Ocular Adnexal MALT LymphomaNot yet recruitingNCT06064344Not applicable
• Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCLNot yet recruitingNCT06062641Phase 2
• Thiotepa, Cyclophosphamide, Clarithromycin and CytarabineRecruitingNCT06060782Phase 1
• Efficacy and Safety of PEG-rhG-CSF Injection for Neutrophil Reconstitution Following AHSCT in Lymphoma/Multiple MyelomaRecruitingNCT06060080Not applicable
• Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study AnalysisRecruitingNCT06058858
• Patient Perspectives in Mantle Cell Lymphoma Clinical ResearchNot yet recruitingNCT06049472
• Tumor Microenvironment Mechanism of LY007 for r/r B-NHL and the Exploration of Novel CAR-T Translational ResearchNot yet recruitingNCT06049381
• Living Well With LymphomaRecruitingNCT06047626Not applicable
• Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell LymphomaRecruitingNCT06047197Phase 1
• JY231 Injection in the Treatment of Relapsed or Refractory B-cell LymphomaRecruitingNCT06045585Early Phase 1
• Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin LymphomaNot yet recruitingNCT06045195Phase 2
• Phase I/II Study of Linperlisib Plus Chidamide for R/R Cutaneous T-cell Lymphoma: a Prospective, Single-center StudyRecruitingNCT06037239Phase 1/2
• Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCLRecruitingNCT06033820Phase 2
• Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem CellsRecruitingNCT06026995Phase 4
• Real-World Study of DLBCL With Different Genetic SubtypesRecruitingNCT06026488
• A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.RecruitingNCT06022029Phase 1
• Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin LymphomaRecruitingNCT06021678Phase 1/2
• TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHLRecruitingNCT06014073Phase 1/2
• CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)RecruitingNCT06002659Phase 1/2
• ZR2 Sequential Immunochemotherapy for Newly Treated MCLRecruitingNCT05992597Phase 2
• The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.Not yet recruitingNCT05990985Not applicable
• Integrative Medicine in Lymphoma SurvivorsRecruitingNCT05982223Not applicable
• Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's LymphomaNot yet recruitingNCT05979857Early Phase 1
• Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell LymphomaNot yet recruitingNCT05979792Early Phase 1
• Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline ChemotherapyRecruitingNCT05977673Phase 2
• XPO-1 in Combination With RCHOP for DH/TH LymphomaRecruitingNCT05974085Phase 2
• Clonal Hematopoiesis of Immunological SignificanceNot yet recruitingNCT05969821
• Obinutuzumab in Chinese Real-world Patients With iNHLNot yet recruitingNCT05968001
• Elastography and Treatment of LymphomaNot yet recruitingNCT05967975
• Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's LymphomaRecruitingNCT05967416Phase 1
• Go-CHOP as the Frontline Therapy for PTCLRecruitingNCT05963347Phase 2
• Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLLRecruitingNCT05963217Phase 1
• Eltrombopag for Peripheral Blood Stem Cell HarvestRecruitingNCT05961410Phase 2
• A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .RecruitingNCT05959694Phase 1/2
• Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell LymphomaRecruitingNCT05958719Phase 2
• Construction of Diagnosis and Treatment System for Primary Vitreoretinal LymphomaRecruitingNCT05950490
• CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory LymphomaRecruitingNCT05948033Phase 1/2
• Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell LeukemiaRecruitingNCT05941156Phase 2
• Study of a Communication Training Intervention for Large B-Cell Lymphoma ProvidersRecruitingNCT05940272Not applicable
• Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingNCT05940051Phase 2
• Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (TRUST)RecruitingNCT05934864
• A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)RecruitingNCT05934513Phase 1/2
• The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients.RecruitingNCT05931328Phase 2
• A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone LymphomaRecruitingNCT05929612Phase 2
• Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana LinfomiRecruitingNCT05929222Phase 3
• Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System InvolvementRecruitingNCT05926427Phase 2
• Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell LymphomaNot yet recruitingNCT05923879
• (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)Not yet recruitingNCT05923502
• Safety and Efficacy Study of KL-7SHRNA Injection Solution in the Treatment of AIDS Patients With LymphomaRecruitingNCT05922384Not applicable
• Biochemical Role of Circulating microRNAs Expression as Diagnostic Markers for Non-Hodgkin's Lymphoma PatientsRecruitingNCT05921812
• Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic ChemotherapyRecruitingNCT05921253Early Phase 1
• Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell LymphomaRecruitingNCT05910801Phase 2
• Safety and Efficacy of Autologous NK Cell Adjuvant Therapy for Relapsed/Refractory Non-Hodgkin's B-cell LymphomaNot yet recruitingNCT05909098Phase 1/2
• A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic MalignanciesRecruitingNCT05908409Phase 1/2
• A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological TypesNot yet recruitingNCT05907447
• Efficacy of Lenalidomide Maintenance in Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma: a Phase II, Open-label, Single-arm StudyNot yet recruitingNCT05901324Phase 2
• A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's LymphomaRecruitingNCT05900765Phase 2
• Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell LymphomaNot yet recruitingNCT05900089Phase 1
• A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FLRecruitingNCT05899621
• Virtual Rehabilitation for Cancer SurvivorsRecruitingNCT05898789Not applicable
• Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic LymphohistiocytosisRecruitingNCT05898477
• CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell LymphomaRecruitingNCT05896813Not applicable
• SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin LymphomaRecruitingNCT05896046Phase 1/2
• A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological TumorsRecruitingNCT05892718Phase 1
• Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)RecruitingNCT05891821Phase 2
• A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCLNot yet recruitingNCT05883709
• GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic MalignanciesRecruitingNCT05880043Phase 1/2
• Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)RecruitingNCT05875428Phase 2
• A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Patients With Extranodal Involvement and Large Tumors Undergoing Immunochemotherapy for PET-CT Assessment of Complete RemissionNot yet recruitingNCT05874778Phase 2
• Glucose Intolerance and Diabetes Related to Treatment With Steroids and PEG- Asparaginase in Children and Adolescents With ALL and LymphomaRecruitingNCT05873322
• A Combination Study of CAR-T Therapy in r/r B-NHLRecruitingNCT05871684Phase 2
• Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell LymphomaRecruitingNCT05868395Phase 2
• Real World Study of Linperlisib for Lymphoma TreatmentNot yet recruitingNCT05863871
• Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCLNot yet recruitingNCT05863845Not applicable
• Impact of a Multidisciplinary End-of-treatment Day Hospital on the Quality of Life of Adolescents and Young Adults With CancerRecruitingNCT05858424Not applicable
• A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin LymphomaRecruitingNCT05852028
• Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic CountriesRecruitingNCT05849857Phase 2
• Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapyRecruitingNCT05848765Phase 2
• Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World StudyRecruitingNCT05846763
• Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone LymphomaRecruitingNCT05846750Phase 2
• TSN222 in Subjects With Advanced Solid Tumors or LymphomasRecruitingNCT05842785Phase 1/2
• Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin LymphomaRecruitingNCT05842707Phase 1/2
• Investigating Cognitive Impairment in Young Patients With Cancer ProspectivelyRecruitingNCT05840575

← Lymphoma overview